Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2011-03-08
2011-03-08
Schwadron, Ron (Department: 1644)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S185100, C424S192100, C514S019300, C514S019600, C514S021200, C530S350000, C530S828000
Reexamination Certificate
active
07901693
ABSTRACT:
Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypeptide; or a T cell that specifically reacts with a WT1 polypeptide. Such compositions may be used, for example, for the prevention and treatment of metastatic diseases.
REFERENCES:
patent: 5350840 (1994-09-01), Call et al.
patent: 5622835 (1997-04-01), Herlyn et al.
patent: 5633142 (1997-05-01), Herlyn et al.
patent: 5670317 (1997-09-01), Ladanyi et al.
patent: 5679356 (1997-10-01), Bonnem et al.
patent: 5693522 (1997-12-01), Chada et al.
patent: 5726288 (1998-03-01), Call et al.
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 6096313 (2000-08-01), Jäger et al.
patent: 6277832 (2001-08-01), Sugiyama et al.
patent: 6316599 (2001-11-01), Call et al.
patent: 6818751 (2004-11-01), Xu et al.
patent: 7063854 (2006-06-01), Gaiger et al.
patent: 7115272 (2006-10-01), Gaiger et al.
patent: 7144581 (2006-12-01), Gaiger et al.
patent: 7316924 (2008-01-01), Bron et al.
patent: 7329410 (2008-02-01), Gaiger et al.
patent: 7553494 (2009-06-01), Gaiger et al.
patent: 2003/0039635 (2003-02-01), Gaiger et al.
patent: 2003/0072767 (2003-04-01), Gaiger et al.
patent: 2004/0018204 (2004-01-01), Gaiger et al.
patent: 1004319 (2000-05-01), None
patent: 1103564 (2001-05-01), None
patent: 06-128299 (1994-05-01), None
patent: WO 91/07509 (1991-05-01), None
patent: WO 94/21287 (1994-09-01), None
patent: WO95/06725 (1995-03-01), None
patent: WO95/29995 (1995-11-01), None
patent: WO 96/38176 (1996-12-01), None
patent: WO 99/03506 (1999-01-01), None
patent: 99/51753 (1999-10-01), None
patent: WO99/58135 (1999-11-01), None
patent: WO 00/06602 (2000-02-01), None
patent: WO 00/18795 (2000-04-01), None
patent: WO 00/26249 (2000-05-01), None
patent: WO 01/25273 (2001-04-01), None
patent: WO 01/60970 (2001-08-01), None
patent: WO 01/62920 (2001-08-01), None
patent: WO 01/72786 (2001-10-01), None
patent: WO 01/94629 (2001-12-01), None
patent: WO 02/00677 (2002-01-01), None
patent: WO 02/28414 (2002-04-01), None
patent: WO 03/037060 (2003-05-01), None
Grosenbach, D.W. et al., “Synergy of Vaccines Strategies to Amplify Antigen-specific Immune Responses and Antitumor Effects,”Cancer Research 61: 4497-4505, Jun. 1, 2001.
Hale, R.S. et al., “Codon Optimization of the Gene Encoding a Domain from Human Type 1 Neurofibromin Protein Results in a Threefold Improvement in Expression Level inEscherichia coli,” Protein Expression and Purification 12: 185-188, 1998.
Oka, Y. et al., “Cancer Immunotherapy Targeting Wilms' Tumor Gene WT1 Product,”The Journal of Immunology 164: 1873-1880, 2000.
Oka, Y. et al., “Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product,”Immunogenetics 51: 99-107, 2000.
Tsuboi, A. et al., “Cytotoxic T-Lymphocyte Responses Elicited to Wilms' Tumor Gene WT1 Product by DNA Vaccination,”Journal of Clinical Immunology 20(3): 195-202, 2000.
TrEMBL Database Accession No. Q93046, Feb. 2, 1997.
Gaiger, A. and Cheever, M.A., “Compositions and Methods for WT1 Specific Immunotherapy,” U.S. Appl. No. 09/164,223, filed Sep. 30, 1998.
Gaiger, A. and Cheever, M.A., “Compositions and Methods for WT1 Specific Immunotherapy,” U.S. Appl. No. 09/276,484, filed Mar. 25, 1999.
Gaiger, A. and Cheever, M.A., “Compositions and Methods for WT1 Specific Immunotherapy,” U.S. Appl. No. 09/684,361, filed Oct. 6, 2000.
Gaiger, A. and Cheever, M.A., “Compositions and Methods for WT1 Specific Immunotherapy,” U.S. Appl. No. 09/685,830, filed Oct. 9, 2000.
Gaiger, A. et al., “Compositions and Methods for WT1 Specific Immunotherapy,” U.S. Appl. No. 09/785,019, filed Feb. 15, 2001.
Boon, T., “Tumor Antigens Recognized by Cytolytic T Lymphocytes: Present Perspectives for Specific Immunotherapy,”Int. J. Cancer 54: 177-180, 1993.
Wu, L.F. et al., “Bacterial Twin-Arginine Signal Peptide-Dependent Protein Translocation Pathway: Evolution and Mechanism,”J. Mol. Microbiol. Biotechnol. 2(2): 179-189, Apr. 2000.
Oka, Y. et al., “Wilms Tumor Gene Peptide-Based Immunotherapy for Patients with Overt Leukemia from Myelodysplastic Syndrome (MDS) or MDS with Myelofibrosis,”International Journal of Hematology 78: 56-61, 2003.
GenBank Database, Accession No. A39692, Feb. 16, 1997.
GenBank Database, Accession No. AAA36810, Jun. 15, 1990.
GenBank Database, Accession No. AAA62825, Oct. 27, 1994.
GenBank Database, Accession No. AAB33427, May 12, 1995.
GenBank Database, Accession No. AAB33443, Jul. 11, 1995.
GenBank Database, Accession No. AAC60039, Nov. 8, 1996.
GenBank Database, Accession No. BAA94794, Apr. 21, 2000.
GenBank Database, Accession No. CAA35956, May 29, 1991.
GenBank Database, Accession No. CAA43819, Dec. 3, 1993.
GenBank Database, Accession No. CAA59736, Feb. 13, 1996.
GenBank Database, Accession No. I51960, Nov. 5, 1999.
GenBank Database, Accession No. M30393, Jun. 15, 1990.
GenBank Database, Accession No. NM—000378, Nov. 5, 2000.
GenBank Database, Accession No. NM—024424, Mar. 20, 2001.
GenBank Database, Accession No. NM—024426, Mar. 20, 2001.
GenBank Database, Accession No. NP—000369, Nov. 5, 2000.
GenBank Database, Accession No. NP—077742, Mar. 20, 2001.
GenBank Database, Accession No. NP—077743, Mar. 20, 2001.
GenBank Database, Accession No. NP—077744, Mar. 20, 2001.
GenBank Database, Accession No. NP—113722, Apr. 6, 2003.
GenBank Database, Accession No. O62651, Nov. 1, 1998.
GenBank Database, Accession No. P50902, Oct. 1, 1996.
GenBank Database, Accession No. S75264, Jul. 11, 1995.
GenBank Database, Accession No. X51630, May 29, 1991.
Derwent Geneseq Database, Accession No. AAT45130, Aug. 19, 1997.
Derwent Geneseq Database, Accession No. AAT45131, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45132, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45133, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45134, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45135, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45136, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45137, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45138, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45139, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45140, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45141, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT45142, Aug. 20, 1997.
Derwent Geneseq Database, Accession No. AAT97855, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97856, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97857, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97858, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97859, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97860, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97861, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97862, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97863, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97864, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97865, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97866, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97867, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAT97868, Mar. 9, 1998.
Derwent Geneseq Database, Accession No. AAX15839, May 11, 1999.
Derwent Geneseq Database, Accession No. AAX15840, May 11, 1999.
Derwent Geneseq Database, Accession No. AAX15841, May 11, 1999.
Derwent Geneseq Database, Accession No. AAX15842, May 11, 1999.
Derwent Geneseq Database, Accession No. AAX15843, May 11, 1999.
Derwent Geneseq Database, Accession No. AAX15844, May 11, 1999.
Derwent Geneseq Database, Acce
Cheever Martin A
Gaiger Alexander
Corixa Corporation
Schwadron Ron
Seed IP Law Group PLLC
LandOfFree
Compositions and methods for WT1 specific immunotherapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for WT1 specific immunotherapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for WT1 specific immunotherapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2751025